{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:25Z","timestamp":1762865845395,"version":"3.38.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejphar.2011.07.031","type":"journal-article","created":{"date-parts":[[2011,8,7]],"date-time":"2011-08-07T03:16:17Z","timestamp":1312686977000},"page":"51-58","source":"Crossref","is-referenced-by-count":14,"title":["The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D2 and serotonin 5-HT1A receptors"],"prefix":"10.1016","volume":"669","author":[{"given":"Peter","family":"Heusler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth","family":"Bruins Slot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Tourette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Cussac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.07.031_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0010","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1073\/pnas.1037595100","article-title":"Agonist unbinding from receptor dictates the nature of deactivation kinetics of G protein-gated K+ channels","volume":"100","author":"Benians","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0015","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","article-title":"Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability","volume":"68","author":"Bishara","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0025","doi-asserted-by":"crossref","first-page":"47512","DOI":"10.1074\/jbc.M108652200","article-title":"Activation and deactivation kinetics of \u03b12A and \u03b12B-adrenergic receptor-activated inwardly rectifying K+ channel currents","volume":"276","author":"Bunemann","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0030","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist","volume":"315","author":"Burstein","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00213-002-1043-0","article-title":"Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)1A receptors","volume":"162","author":"Cussac","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"year":"2008","series-title":"Distinct affinity profile of novel antipsychotics possessing combined D2 and 5-HT 1A receptor properties compared with conventional and atypical antipsychotics","author":"Cussac","key":"10.1016\/j.ejphar.2011.07.031_bb0050"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/jpet.109.156307","article-title":"Mutant 5-hydroxytryptamine1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology","volume":"331","author":"Cussac","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4088\/PCC.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim. Care Companion. J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0065","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.lfs.2003.07.005","article-title":"The [35S]GTP\u03b3S binding assay: approaches and applications in pharmacology","volume":"74","author":"Harrison","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2006.08.063","article-title":"Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist","volume":"552","author":"Heinrich","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuropharm.2005.05.001","article-title":"Differential ion current activation by human 5-HT1A receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling","volume":"49","author":"Heusler","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0090","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.neuropharm.2006.11.008","article-title":"Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels","volume":"52","author":"Heusler","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00210-008-0333-4","article-title":"Activation of G proteins and extracellular signal-regulated kinase 1\/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists","volume":"379","author":"Heusler","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0100","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1074\/jbc.M008213200","article-title":"Inhibition of a Gi-activated potassium channel (GIRK1\/4) by the Gq-coupled m1 muscarinic acetylcholine receptor","volume":"276","author":"Hill","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0105","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuropharm.2008.05.025","article-title":"Serotonergic approaches in the development of novel antipsychotics","volume":"55","author":"Jones","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1503\/jpn.100055","article-title":"Clozapine: a distinct, poorly understood and under-used molecule","volume":"35","author":"Joober","year":"2010","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.pnpbp.2006.09.007","article-title":"Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling","volume":"31","author":"Jordan","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0120","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","article-title":"Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia","volume":"6","author":"Kim","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1074\/jbc.270.2.589","article-title":"Agonist-induced desensitization of the \u03bc opioid receptor-coupled potassium channel (GIRK1)","volume":"270","author":"Kovoor","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0922-4106(93)90126-T","article-title":"Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists","volume":"245","author":"Kuoppamaki","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","article-title":"Pharmacology of N-desmethylclozapine","volume":"115","author":"Lameh","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0145","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0150","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0028-3908(00)00080-0","article-title":"Regulation of GIRK channel deactivation by G\u03b1q and G\u03b1i\/o pathways","volume":"39","author":"Mark","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/WNF.0b013e31818d46f5","article-title":"N-desmethylclozapine: is there evidence for its antipsychotic potential?","volume":"32","author":"Mendoza","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.104.069625","article-title":"The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis","volume":"311","author":"Millan","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0170","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.npp.1301279","article-title":"Evaluation of N-desmethylclozapine as a potential antipsychotic\u2014preclinical studies","volume":"32","author":"Natesan","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0028-3908(95)00170-0","article-title":"Clozapine is a partial agonist at cloned, human 5-HT1A receptors","volume":"35","author":"Newman-Tancredi","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1461145707008061","article-title":"Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells","volume":"11","author":"Newman-Tancredi","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0185","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1471-4159.2007.04660.x","article-title":"Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation","volume":"102","author":"Novi","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0190","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/PL00005090","article-title":"Stimulated [35S]GTP\u03b3S binding by 5-HT1A receptor agonists in recombinant cell lines. Modulation of apparent efficacy by G-protein activation state","volume":"356","author":"Pauwels","year":"1997","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0022-3565(24)29520-3","article-title":"Dynamic dopamine-antagonist interactions at recombinant human dopamine D2short receptor: dopamine-bound versus antagonist-bound receptor states","volume":"297","author":"Pauwels","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0200","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0022-3565(25)24566-9","article-title":"Metabolism and bioactivation of clozapine by human liver in vitro","volume":"272","author":"Pirmohamed","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0205","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2008.06.029","article-title":"Electrophysiology-based analysis of human histamine H4 receptor pharmacology using GIRK channel coupling in Xenopus oocytes","volume":"591","author":"Sahlholm","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0215","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1176\/appi.ajp.162.10.1984-a","article-title":"An update of fast-off dopamine D2 atypical antipsychotics","volume":"162","author":"Seeman","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0220","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1085\/jgp.109.4.477","article-title":"Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes","volume":"109","author":"Sharon","year":"1997","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0225","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0230","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s004240050604","article-title":"Agonist-independent inactivation and agonist-induced desensitization of the G protein-activated K+ channel (GIRK) in Xenopus oocytes","volume":"436","author":"Vorobiov","year":"1998","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ejphar.2011.07.031_bb0245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2011.07.031_bb0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1113\/jphysiol.2002.032151","article-title":"Gating properties of GIRK channels activated by G\u03b1o- and G\u03b1i-coupled muscarinic m2 receptors in Xenopus oocytes: the role of receptor precoupling in RGS modulation","volume":"545","author":"Zhang","year":"2002","journal-title":"J. Physiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911008235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911008235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T09:06:08Z","timestamp":1741424768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911008235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":50,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0014299911008235"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.07.031","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}